Polivy Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of diffuse large b-cell lymphoma, advancements in monoclonal antibody development, expansion of oncology treatment centers, rising adoption of targeted cancer therapies, improved diagnostic capabilities.

The growth in the forecast period can be attributed to increasing demand for personalized oncology drugs, rising investments in adc research pipelines, expansion of first-line combination therapies, growing focus on treatment-resistant lymphomas, increasing regulatory approvals for targeted biologics. Major trends in the forecast period include increasing adoption of antibody-drug conjugates, rising use in targeted lymphoma therapies, growing integration with combination chemotherapy regimens, expansion of precision oncology treatments, enhanced focus on cd79b-targeted drugs.

The increasing incidence of diffuse large B-cell lymphoma (DLBCL) is expected to drive the growth of the Polivy market. DLBCL, the most common type of non-Hodgkin lymphoma (NHL), is a highly aggressive blood cancer originating from B-lymphocytes, which are vital white blood cells responsible for antibody production. The rising incidence of DLBCL can be attributed to factors like an aging population, increased rates of immunosuppression from conditions such as HIV/AIDS and organ transplants, and environmental factors contributing to the disease's development. Polivy is used in combination with chemotherapy to treat relapsed or refractory DLBCL in patients who have received prior treatments. For example, in July 2024, the Royal College of Pathologists, a UK-based professional membership organization, reported that around 5,500 individuals in the UK are diagnosed with DLBCL each year, with about 30% experiencing refractory disease or relapse soon after their initial treatment. Consequently, the rising incidence of DLBCL is fueling the growth of the Polivy market.

The rising number of oncology procedures is also expected to drive the growth of the Polivy market. Oncology procedures, which include medical tests, treatments, and interventions to diagnose and treat cancer, are increasing as healthcare providers and patients focus on early cancer detection and access to effective targeted therapies. Polivy plays an important role in these procedures by offering targeted therapy that enhances outcomes and expands treatment options for cancer patients. For instance, in February 2024, the World Health Organization predicted that over 35 million new cancer cases would be reported in 2050, a 77% increase from the estimated 20 million cases in 2022. As a result, the growing number of oncology procedures is propelling the growth of the Polivy market.

Major companies operating in the Polivy market are focusing on developing innovative regimens, such as first-line antibody-drug conjugate (ADC) combinations, to target aggressive B-cell lymphomas and improve patient outcomes. These first-line ADC combinations use a monoclonal antibody that selectively binds to tumor-specific proteins, coupled with a cytotoxic payload, offering more targeted therapy than conventional chemotherapy, which can affect both cancerous and healthy cells. For example, in April 2023, Genentech received FDA approval for Polivy (polatuzumab vedotin-piiq) in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) in adults. Polivy, developed using Seagen’s linker-payload technology, specifically targets the CD79b protein on B-cells, and the conjugated payload (vedotin) disrupts microtubules inside cancer cells, leading to cell death. This combination therapy has shown a 27% reduction in the risk of progression or death compared to standard R-CHOP in the pivotal POLARIX study, offering high specificity to malignant B-cells and a more favorable safety profile compared to systemic chemotherapy. This regimen is poised to transform first-line treatment for DLBCL by potentially reducing relapse rates and improving long-term patient outcomes.

Major companies operating in the polivy market are F. Hoffmann-La Roche Ltd (Genentech Inc.)

North America was the largest region in the polivy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polivy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polivy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the polivy market by increasing costs of imported monoclonal antibody components, cytotoxic payload materials, specialized manufacturing equipment, and cold-chain distribution systems. Oncology centers in North America and Europe are most affected due to reliance on globally sourced biologic inputs, while Asia-Pacific faces higher costs in drug importation and clinical distribution. These tariffs elevate treatment costs and affect reimbursement dynamics. However, they are also driving localized biologics manufacturing, regional oncology drug production, and long-term supply chain resilience for advanced cancer therapeutics.

The polivy market research report is one of a series of new reports that provides polivy market statistics, including polivy industry global market size, regional shares, competitors with a polivy market share, detailed polivy market segments, market trends and opportunities, and any further data you may need to thrive in the polivy industry. This polivy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Polivy (polatuzumab vedotin) is an antibody-drug conjugate used for treating diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma. It is specifically indicated for adult patients with relapsed or refractory DLBCL who have undergone at least two prior therapies. Polivy can also be used as a first-line treatment in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for patients with moderate- to high-risk diffuse large B-cell lymphoma.

The primary indications for Polivy are previously untreated DLBCL and relapsed or refractory DLBCL. Previously untreated DLBCL refers to a form of cancer affecting white blood cells that has not received any prior treatment. It is generally an aggressive form of lymphoma that requires immediate medical intervention. Polivy is used as part of combination therapy to effectively address this condition. The drug is administered as an injectable solution and is distributed through various channels, including direct sales, pharmaceutical wholesalers, and online pharmacies.

The polivy market consists of sales of polivy (polatuzumab vedotin) injections in 30 mg and 140 mg vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.